RAPT Therapeutics, Inc.
561 Eccles Avenue
South San Francisco
58 articles with RAPT Therapeutics, Inc.
FLX Bio Highlights Preclinical Atopic Dermatitis and Asthma Data for FLX193 at the American Association of Immunologists (AAI) Annual Meeting 2019
FLX193 Presents Potentially Attractive Alternative to Treatment with Injectable Biologics or Topical Corticosteroids
FLX Bio, Inc. announced that Brian Wong, M.D., Ph.D., CEO will present a corporate update and company overview at the Cowen and Company 39th Annual Health Care Conference on Monday, March 11, 2019 at 3:00 p.m. ET in Boston, MA.
Brian Wong, M.D., Ph.D., CEO will present at the 37th Annual J.P. Morgan Healthcare Conference on Wednesday, January 9, 2019 at 7:30 a.m. Pacific Standard Time in San Francisco, CA.
FLX Bio, Inc., a clinical-stage, biopharmaceutical company focused on the development of oral small-molecule drugs that target immune drivers of cancer and other immune-related disorders, today announced that Brian Wong, M.D., Ph.D., CEO and Rekha Hemrajani, COO will participate in an analyst-led fireside chat at the Evercore ISI HealthCONx
Data Confirm FLX475 Offers Potential for Selectively Targeting Tumor Regulatory T Cells
FLX Bio Announces Clinical Trial Collaboration Agreement With Merck for Ongoing Phase 1/2 Study of FLX475
Trial will evaluate FLX Bio’s CCR4 inhibitor, FLX475, in combination with Merck’s KEYTRUDA® (pembrolizumab), an anti-PD-1 therapy, in multiple types of cancer
FLX Bio Announces First Patient Dosed With FLX475, a Best-in-Class CCR4 Inhibitor for the Treatment of Multiple Cancers
FLX Bio, Inc., a clinical-stage, biopharmaceutical company, today announced that the first patient has been treated in its Phase 1/2 clinical trial of FLX475 in patients with various advanced cancers.
FLX Bio, Inc. announced that Brian Wong, M.D., Ph.D., CEO will present at the 2018 Wedbush PacGrow Healthcare Conference on August 15, 2018 at 12:45 p.m. ET in New York.
FLX Bio, Inc. announced that Brian Wong, M.D., Ph.D., President and CEO will present at the Jefferies Global Healthcare Conference.
FLX Bio to Highlight New Preclinical Data from CCR4 and USP7 Programs at the American Academy for Cancer Research Annual Meeting
American Association for Cancer Research (AACR) Annual Meeting to be held April 14 through April 18, 2018 in Chicago, IL
FLX Bio today announced the appointment of senior pharmaceutical research and development executive Michael F. Giordano, M.D., to its Board of Directors.
Dr. Brockstedt joins FLX Bio most recently from Aduro Biotech, where he served in a number of escalating positions, most recently as Executive Vice President of Research and Development.
12/21/2017New investors included GV and undisclosed investors.